Related Experiment Video
Updated: Jan 13, 2026

Locomotor Assessment of 6-Hydroxydopamine-induced Adult Zebrafish-based Parkinson's Disease Model
Published on: December 28, 2021
Tiny Fish, Big Hope: Zebrafish Unlocking Secrets to Fight Parkinson's Disease
Manjunatha Bangeppagari1, Akshatha Manjunath1, Anusha Srinivasa1
1Zebrafish Drug Screening Center, Department of Cell Biology and Molecular Genetics, Sri Devaraj Urs Academy of Higher Education and Research (A Deemed to Be University), Tamaka, Kolar 563103, India.
None:
Parkinson's disease (PD) is a progressive neurological disorder marked by the gradual loss of dopamine-producing neurons in the brain. This neuronal degradation causes motor symptoms such as tremors, stiffness, and slowness of movement. Despite decades of research, current treatments remain limited to symptom management, highlighting the urgent need for deeper insights into PD mechanisms and new therapeutic approaches. Among model organisms, zebrafish (Danio rerio) have emerged as a valuable tool for PD research due to the possibility of genetic manipulation. Zebrafish can be engineered to carry human PD-associated mutations, such as those in α-synuclein, LRRK2, and Parkin, enabling researchers to study the molecular and cellular basis of the disease. Additionally, exposure to neurotoxins like MPTP and paraquat allows scientists to replicate PD-like symptoms in zebrafish, supporting drug screening and behavioural analysis. This review summarises the key advantages and limitations of zebrafish as a model for PD, compares it with rodent models, and discusses recent advances and future directions that may improve translational outcomes in PD therapy and personalised medicine.

